{"gene":"SMYD5","run_date":"2026-06-10T07:46:37","timeline":{"discoveries":[{"year":2022,"finding":"SMYD5 is a histone methyltransferase that catalyzes H3K36me3 at promoter regions (distinct from SETD2-mediated H3K36me3 at gene bodies). SMYD5 is recruited to chromatin by RNA polymerase II, and its enzymatic activity depends on its C-terminal glutamic acid-rich domain; overexpression of full-length but not C-terminal domain-truncated Smyd5 restores H3K36me3 at promoters in knockout cells.","method":"ChIP-seq, Smyd5 knockout rescue with full-length vs. truncated constructs, in vitro methyltransferase assay","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro enzymatic assay, domain truncation mutagenesis, and KO rescue with orthogonal ChIP-seq validation in a single rigorous study","pmids":["35680905"],"is_preprint":false},{"year":2024,"finding":"SMYD5 trimethylates the core ribosomal protein RPL40 (ubiquitin fusion protein partner) at lysine 22 (rpL40K22me3). This modification regulates mRNA translation output; loss of SMYD5 leads to reduced translation output and increased ribosome collisions indicative of disturbed elongation. Identified by a biochemical-proteomics strategy as the principal physiological substrate of SMYD5.","method":"Biochemical-proteomics (mass spectrometry), in vitro methyltransferase assay, ribosome profiling/polysome analysis, SMYD5 ablation in cell lines and mouse models","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro assay, MS-based substrate identification, replicated independently in multiple labs (PMID:39048817, PMID:39103523, PMID:40184250)","pmids":["39048817"],"is_preprint":false},{"year":2024,"finding":"SMYD5 has robust in vitro methyltransferase activity toward RPL40 K22 and primarily catalyzes RPL40 K22me3 in cells. Loss of SMYD5 and RPL40 K22me3 reduces translation output and causes increased ribosome collisions. SMYD5 and RPL40 K22me3 are upregulated in hepatocellular carcinoma.","method":"In vitro methyltransferase assay with recombinant SMYD5, SMYD5 knockout cell lines, ribosome fractionation/polysome profiling, genetically engineered mouse models and PDX models","journal":"Cell research","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with recombinant protein, KO cells, polysome profiling, and in vivo mouse models; replicates findings from concurrent independent studies","pmids":["39103523"],"is_preprint":false},{"year":2025,"finding":"SMYD5 trimethylates RPL40/eL40 at lysine 22 through recognition of a KXY motif (tyrosine at the +2 position is required). Active site mutations abolish this activity. SMYD5 does not methylate histones in vitro, and its requirement for the KXY motif explains this lack of activity toward canonical histone substrates. SMYD5 KO in K562 cells causes complete loss of RPL40 K22 methylation and decreased polysome levels.","method":"In vitro methyltransferase assay with recombinant SMYD5 and synthetic peptides, active-site mutagenesis, SMYD5 KO in K562 cells, mass spectrometry, systematic recognition motif analysis","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with mutagenesis, systematic motif analysis, KO validation, and negative result for histone substrates; all orthogonal methods in one study","pmids":["40184250"],"is_preprint":false},{"year":2025,"finding":"SMYD5 does not methylate histones in vitro (negative finding). Systematic analysis of its recognition motif shows SMYD5 requires a KXY motif, and the absence of a tyrosine at +2 in canonical histone substrates explains its lack of histone methyltransferase activity.","method":"In vitro methyltransferase assay with recombinant SMYD5 toward histone substrates, systematic peptide motif analysis","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1 / Moderate — rigorous in vitro assay with systematic motif mapping; explicitly tested and rejected histone substrates","pmids":["40184250"],"is_preprint":false},{"year":2017,"finding":"SMYD5 mediates H4K20me3 at heterochromatin regions in embryonic stem cells. Depletion of SMYD5 leads to global decreases in H4K20me3 levels, redistribution of heterochromatin constituents (H3K9me3/2, G9a, HP1α), and de-repression of endogenous retroelements (LTR, LINE elements). Loss of SMYD5-dependent heterochromatin silencing near genic regions upregulates lineage-specific genes, compromising ES cell self-renewal.","method":"ChIP-seq, SMYD5 knockdown in mouse ES cells, Western blot for histone marks, repeat element expression analysis","journal":"Epigenetics & chromatin","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean KD with defined epigenomic phenotype, ChIP-seq, multiple histone mark readouts; single lab but multiple orthogonal methods","pmids":["28250819"],"is_preprint":false},{"year":2017,"finding":"SMYD5 depletion during ES cell differentiation causes genome-wide decreases in H4K20me3 and H3K9me3, derepression of LTR and LINE repetitive elements, chromosomal aberrations, and formation of transformed cells with a cancer-like expression signature. Depletion of SMYD5 in human colon and lung cancer cells increases tumor growth.","method":"SMYD5 depletion in mouse ES cells during differentiation, ChIP-seq, cytogenetics/karyotyping, xenograft tumor assays","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KD with defined cellular phenotypes (chromosomal aberrations, epigenomic changes), multiple orthogonal methods, single lab","pmids":["28951459"],"is_preprint":false},{"year":2022,"finding":"SMYD5 interacts with PGC-1α (co-immunoprecipitation) and mediates lysine methylation of PGC-1α, subsequently facilitating its ubiquitination and degradation. This post-translational mechanism attenuates mitochondrial biogenesis, respiration, and function in intestinal epithelial cells. Smyd5 conditional knockout in IECs protects mice from DSS-induced colitis.","method":"Co-immunoprecipitation, in vitro methylation assay with mass spectrometry identification of methylated lysines, cycloheximide chase assay, Smyd5 conditional KO mice with colitis model, Seahorse respirometry","journal":"Cellular and molecular gastroenterology and hepatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP, in vitro methylation with MS, degradation assay, and in vivo KO model; single lab but multiple orthogonal methods","pmids":["35643234"],"is_preprint":false},{"year":2023,"finding":"SMYD5 associates in vivo with the HIV-1 promoter, binds the HIV-1 TAR element RNA and Tat protein, and methylates Tat in vitro. SMYD5 activates the HIV-1 promoter with or without Tat; knockdown of SMYD5 decreases HIV-1 transcription in cell lines and primary CD4+ T cells. Tat expression increases SMYD5 protein levels in a manner dependent on the Tat cofactor USP11.","method":"ChIP assay (in vivo promoter association), RNA binding assay (TAR element), in vitro methylation assay (Tat substrate), SMYD5 knockdown in cell lines and primary T cells, HIV-1 transcription reporter assays","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro methylation of Tat, ChIP, RNA binding, and functional KD in primary cells; single lab, multiple orthogonal methods","pmids":["36897778"],"is_preprint":false},{"year":2024,"finding":"SMYD5 represses the key mild hypothermia response (MHR) gene SP1 at euthermia; this repression correlates with temperature-dependent levels of H3K36me3 at the SP1 locus and globally, identified through a forward CRISPR-Cas9 mutagenesis screen.","method":"Forward CRISPR-Cas9 mutagenesis screen, ChIP analysis for H3K36me3, transcriptional reporter/gene expression assays","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR screen plus correlative H3K36me3 ChIP; mechanistic link to SMYD5 enzymatic activity inferred but not directly demonstrated via mutagenesis","pmids":["39083378"],"is_preprint":false},{"year":2016,"finding":"Loss of Smyd5 in zebrafish (morpholino knockdown and CRISPR/Cas9 knockout) leads to increased expression of primitive and definitive hematopoietic markers (pu.1, mpx, l-plastin, cmyb), establishing a role for Smyd5 in restraining myeloid hematopoiesis during embryogenesis.","method":"Morpholino knockdown, CRISPR/Cas9 knockout in zebrafish embryos, in situ hybridization and RT-PCR for hematopoietic markers","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two independent loss-of-function approaches (MO + CRISPR) with consistent phenotypic readout in zebrafish; no direct biochemical mechanism defined","pmids":["27377701"],"is_preprint":false},{"year":2022,"finding":"AlphaFold structural modeling of SMYD5 reveals an incomplete target lysine access channel lacking the evolutionarily conserved tri-aromatic arrangement, which correlates with low H3/H4 histone catalytic activity. SMYD5 contains a C-terminal poly-glutamic acid tract and a 30-residue MYND domain insertion that regulate structural stability, and a predicted N-terminal mitochondrial targeting signal containing a non-classical nuclear localization signal.","method":"AlphaFold structural prediction validated by comparison to known SMYD crystal structures using inter-residue distance maps; thermal stability assays","journal":"Biomolecules","confidence":"Low","confidence_rationale":"Tier 4 / Weak — primarily computational structural prediction with some biochemical correlation; no direct experimental structure determination or mutagenesis of active site residues","pmids":["35740908"],"is_preprint":false},{"year":2021,"finding":"Protamine (a histone substitute in chromatin condensation during spermatogenesis) enhances SMYD5 thermal stability and physically interacts with SMYD5. The interaction is independent of the poly-E tract and MYND domain insertion. The C-terminal poly-glutamic acid tract and MYND domain M-insertion also regulate SMYD5 structural stability. Protamine has opposite (destabilizing) effects on the closely related SMYD2.","method":"Thermal stability assay (DSF), machine learning-assisted screening (Silver Bullets Bio library), co-precipitation/binding assays for protamine-SMYD5 interaction","journal":"Biochemical and biophysical research communications","confidence":"Low","confidence_rationale":"Tier 3 / Weak — thermal stability and binding assays in a single study; functional consequence of protamine-SMYD5 interaction not established","pmids":["33676231"],"is_preprint":false},{"year":2024,"finding":"SMYD5 knockdown in lung cancer cell lines reduces H4K20 trimethylation at the SH2B3 locus, leading to increased SH2B3 expression and inhibition of cell migration and invasion via changes in epithelial-mesenchymal transition markers and MMP9 expression.","method":"SMYD5 knockdown in NCI-H1299 and H1703 cell lines, ChIP for H4K20me3, migration/invasion assays, EMT marker analysis","journal":"Molecules and cells","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single KD approach, correlative ChIP without direct methyltransferase activity demonstration","pmids":["38723947"],"is_preprint":false},{"year":2025,"finding":"SMYD5 mediates methylation of FoxO1 in fibroblast-like synoviocytes, which accelerates FoxO1 degradation through ubiquitination, promoting FLS proliferation. Additionally, SMYD5 promotes upregulation of hexokinase-2 (HK2), increasing lactate release and activating NF-κB signaling to intensify inflammation in FLS.","method":"Loss-of-function and gain-of-function experiments in FLS, co-immunoprecipitation (inferred from context), AAV-mediated KD in CIA mouse model, downstream pathway analysis","journal":"Cellular & molecular biology letters","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, mechanistic details (direct methylation of FoxO1) described but no explicit in vitro methylation assay reported in abstract","pmids":["40165083"],"is_preprint":false},{"year":2025,"finding":"SMYD5 physically interacts with BRD4 in hepatocellular carcinoma cells; this interaction is identified as a potential therapeutic axis. Knockdown of SMYD5 inhibits cell proliferation and increases apoptosis in LIHC cell lines.","method":"Co-immunoprecipitation (interaction), functional knockdown assays, bioinformatics/in silico docking","journal":"Pharmaceuticals (Basel, Switzerland)","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, interaction reported but mechanistic detail of BRD4-SMYD5 functional axis not fully characterized in the abstract","pmids":["40872497"],"is_preprint":false}],"current_model":"SMYD5 is a SET and MYND domain-containing lysine methyltransferase whose principal physiological substrate is the ribosomal protein RPL40, which it trimethylates at lysine 22 via recognition of a KXY motif to promote translation elongation; SMYD5 also catalyzes H3K36me3 at gene promoters (recruited by RNA Pol II) to regulate gene expression, and has been shown to methylate non-histone proteins including PGC-1α (promoting its ubiquitin-dependent degradation to impair mitochondrial function) and the HIV-1 Tat protein (activating viral transcription), while its role in H4K20me3-marked heterochromatin maintenance in stem cells—previously its primary described function—may reflect indirect effects given that in vitro evidence argues against direct histone methylation activity."},"narrative":{"mechanistic_narrative":"SMYD5 is a SET- and MYND-domain lysine methyltransferase whose principal physiological substrate is the core ribosomal protein RPL40/eL40, which it trimethylates at lysine 22 to support mRNA translation [PMID:39048817, PMID:39103523]. Substrate selection is governed by recognition of a KXY motif requiring a tyrosine at the +2 position, and active-site mutations abolish catalysis [PMID:40184250]. Loss of SMYD5 eliminates RPL40 K22me3, reduces translation output, increases ribosome collisions indicative of disturbed elongation, and lowers polysome levels [PMID:39048817, PMID:39103523, PMID:40184250]. SMYD5 and RPL40 K22me3 are upregulated in hepatocellular carcinoma [PMID:39103523]. Beyond this ribosomal role, SMYD5 catalyzes H3K36me3 at promoter regions in a manner dependent on its C-terminal glutamic acid-rich domain and is recruited to chromatin by RNA polymerase II, distinct from SETD2-mediated H3K36me3 at gene bodies [PMID:35680905]. SMYD5 also methylates non-histone proteins: it methylates PGC-1α to promote its ubiquitin-dependent degradation, attenuating mitochondrial biogenesis and respiration [PMID:35643234], and methylates the HIV-1 Tat protein while associating with the HIV-1 promoter and TAR RNA to activate viral transcription [PMID:36897778]. In vitro reconstitution with recombinant SMYD5 shows no direct methylation of canonical histones, since these substrates lack the required +2 tyrosine, indicating that earlier-described H4K20me3-related heterochromatin functions in stem and cancer cells [PMID:28250819, PMID:28951459] reflect activities not explained by direct histone methylation [PMID:40184250]. No experimentally determined structure of SMYD5 is available in this corpus.","teleology":[{"year":2017,"claim":"Established the first proposed chromatin function of SMYD5, linking it to H4K20me3-marked heterochromatin maintenance, retroelement silencing, and stem cell self-renewal versus tumorigenesis.","evidence":"SMYD5 knockdown/depletion in mouse ES cells with ChIP-seq, histone mark Westerns, repeat element expression, cytogenetics, and xenograft assays","pmids":["28250819","28951459"],"confidence":"Medium","gaps":["No direct in vitro demonstration that SMYD5 methylates H4K20","Effects could be indirect rather than via direct catalysis","Recruitment mechanism to heterochromatin undefined"]},{"year":2016,"claim":"Demonstrated an in vivo developmental role for Smyd5 in restraining myeloid hematopoiesis, the first organismal phenotype for the gene.","evidence":"Morpholino knockdown and CRISPR/Cas9 knockout in zebrafish with in situ hybridization and RT-PCR for hematopoietic markers","pmids":["27377701"],"confidence":"Medium","gaps":["No biochemical substrate or molecular mechanism defined","Does not connect phenotype to a specific methylation event"]},{"year":2022,"claim":"Resolved SMYD5's chromatin enzymatic activity by assigning it promoter-localized H3K36me3 distinct from SETD2 gene-body marks and showing the C-terminal domain is required for activity.","evidence":"ChIP-seq, knockout rescue with full-length versus truncated constructs, and in vitro methyltransferase assay","pmids":["35680905"],"confidence":"High","gaps":["Reconciliation with later negative histone methylation results unresolved","Mechanism of RNA Pol II-mediated recruitment not detailed"]},{"year":2022,"claim":"Extended SMYD5 to non-histone substrate methylation by showing it methylates PGC-1α to drive its degradation, coupling SMYD5 to mitochondrial function and intestinal inflammation.","evidence":"Co-IP, in vitro methylation with MS, cycloheximide chase, conditional KO mice, and Seahorse respirometry","pmids":["35643234"],"confidence":"Medium","gaps":["Specific methylated lysines and their direct role in ubiquitination not fully mapped","Single lab"]},{"year":2023,"claim":"Identified a host-pathogen role in which SMYD5 binds the HIV-1 promoter, TAR RNA, and Tat, and methylates Tat to activate viral transcription.","evidence":"ChIP, RNA binding assay, in vitro methylation of Tat, and SMYD5 knockdown in cell lines and primary CD4+ T cells","pmids":["36897778"],"confidence":"Medium","gaps":["Site and functional consequence of Tat methylation not fully resolved","Single lab"]},{"year":2024,"claim":"Redefined the principal physiological substrate of SMYD5 as ribosomal protein RPL40 K22, connecting the enzyme directly to translation elongation rather than chromatin.","evidence":"Biochemical-proteomics/MS substrate identification, in vitro methyltransferase assays, ribosome/polysome profiling, and SMYD5 ablation in cells and mouse models, replicated across independent labs","pmids":["39048817","39103523"],"confidence":"High","gaps":["How RPL40 K22me3 mechanistically prevents ribosome collisions unresolved","Relationship between translation role and prior chromatin phenotypes unclear"]},{"year":2025,"claim":"Defined the substrate-recognition logic (KXY motif, +2 tyrosine) and experimentally rejected direct histone methylation, reframing earlier histone-mark phenotypes as likely indirect.","evidence":"In vitro methyltransferase assays with recombinant SMYD5 and synthetic peptides, active-site and motif mutagenesis, MS, and KO validation in K562 cells including negative histone results","pmids":["40184250"],"confidence":"High","gaps":["Mechanistic basis of in-cell H3K36me3 ChIP signals not reconciled with in vitro negativity","Full census of KXY-bearing cellular substrates incomplete"]},{"year":2025,"claim":"Expanded the disease-context substrate and interaction repertoire (FoxO1 methylation/degradation and metabolic-inflammatory signaling in synoviocytes; BRD4 interaction in hepatocellular carcinoma).","evidence":"Loss/gain-of-function in fibroblast-like synoviocytes with AAV KD in a CIA mouse model, and co-IP plus functional knockdown in LIHC cell lines","pmids":["40165083","40872497"],"confidence":"Low","gaps":["No explicit in vitro methylation assay reported for FoxO1","BRD4-SMYD5 functional axis not mechanistically characterized","Single-lab, correlative associations"]},{"year":null,"claim":"It remains unresolved how SMYD5's ribosomal RPL40 methylation activity mechanistically relates to the chromatin-associated H3K36me3 and heterochromatin phenotypes attributed to it, and whether the latter depend on its catalytic activity.","evidence":"","pmids":[],"confidence":"Low","gaps":["No experimental structure of SMYD5","No unifying model linking translation and chromatin functions","Direct catalytic basis of in-cell histone marks undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,1,2,3,7,8]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[1,2,3,7,8]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[8]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,5,8]},{"term_id":"GO:0005840","term_label":"ribosome","supporting_discovery_ids":[1,2,3]}],"pathway":[{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[1,2,3]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[0,5,6]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[7]}],"complexes":[],"partners":["RPL40","PGC-1Α","TAT","BRD4","FOXO1","PROTAMINE"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q6GMV2","full_name":"Protein-lysine N-trimethyltransferase SMYD5","aliases":["Protein NN8-4AG","Retinoic acid-induced protein 15","SET and MYND domain-containing protein 5","[histone H3]-lysine20 N-trimethyltransferase SMYD5","[histone H4]-lysine36 N-trimethyltransferase SMYD5"],"length_aa":418,"mass_kda":47.3,"function":"Protein-lysine N-trimethyltransferase that specifically catalyzes trimethylation of 'Lys-22' of the RPL40/eL40 subunit of the 60S ribosome, thereby promoting translation elongation and protein synthesis (PubMed:39048817, PubMed:39103523). May also act as a histone methyltransferase in the context of histone octamers, but not on nucleosome substrates: trimethylates 'Lys-36' of histone H3 and 'Lys-20' of histone H4 to form H3K36me3 and H4K20me3, respectively (By similarity). The histone methyltransferase activity, which is independent of its SET domain, is however unsure in vivo (PubMed:39048817, PubMed:39103523). In association with the NCoR corepressor complex, involved in the repression of toll-like receptor 4 (TLR4)-target inflammatory genes in macrophages, possibly by catalyzing the formation of H4K20me3 at the gene promoters (By similarity). Plays an important role in embryonic stem (ES) cell self-renewal and differentiation (By similarity). Maintains genome stability of ES cells during differentiation through regulation of heterochromatin formation and repression of endogenous repetitive DNA elements by promoting H4K20me3 marks (PubMed:28951459). Acts as a regulator of the hypothermia response: its degradation in response to mild hypothermia relieves the formation of H3K36me3 at gene promoters, allowing expression of the neuroprotective gene SP1 (By similarity)","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q6GMV2/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SMYD5","classification":"Not Classified","n_dependent_lines":25,"n_total_lines":1208,"dependency_fraction":0.020695364238410598},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SMYD5","total_profiled":1310},"omim":[{"mim_id":"619114","title":"SET AND MYND DOMAIN-CONTAINING PROTEIN 5; SMYD5","url":"https://www.omim.org/entry/619114"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/SMYD5"},"hgnc":{"alias_symbol":["RRG1","NN8-4AG","ZMYND23"],"prev_symbol":["RAI15"]},"alphafold":{"accession":"Q6GMV2","domains":[{"cath_id":"2.170.270.10","chopping":"6-54_309-387","consensus_level":"medium","plddt":92.9402,"start":6,"end":387},{"cath_id":"-","chopping":"58-256","consensus_level":"high","plddt":91.4938,"start":58,"end":256}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q6GMV2","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q6GMV2-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q6GMV2-F1-predicted_aligned_error_v6.png","plddt_mean":88.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SMYD5","jax_strain_url":"https://www.jax.org/strain/search?query=SMYD5"},"sequence":{"accession":"Q6GMV2","fasta_url":"https://rest.uniprot.org/uniprotkb/Q6GMV2.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q6GMV2/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q6GMV2"}},"corpus_meta":[{"pmid":"17392518","id":"PMC_17392518","title":"The response regulator RRG-1 functions upstream of a mitogen-activated protein kinase pathway impacting asexual development, female fertility, osmotic stress, and fungicide resistance in Neurospora crassa.","date":"2007","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/17392518","citation_count":80,"is_preprint":false},{"pmid":"28250819","id":"PMC_28250819","title":"SMYD5 regulates H4K20me3-marked heterochromatin to safeguard ES cell self-renewal and prevent spurious differentiation.","date":"2017","source":"Epigenetics & chromatin","url":"https://pubmed.ncbi.nlm.nih.gov/28250819","citation_count":55,"is_preprint":false},{"pmid":"35680905","id":"PMC_35680905","title":"SMYD5 catalyzes histone H3 lysine 36 trimethylation at promoters.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35680905","citation_count":38,"is_preprint":false},{"pmid":"39048817","id":"PMC_39048817","title":"SMYD5 methylation of rpL40 links ribosomal output to gastric cancer.","date":"2024","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/39048817","citation_count":35,"is_preprint":false},{"pmid":"28951459","id":"PMC_28951459","title":"SMYD5 Controls Heterochromatin and Chromosome Integrity during Embryonic Stem Cell Differentiation.","date":"2017","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28951459","citation_count":30,"is_preprint":false},{"pmid":"27377701","id":"PMC_27377701","title":"Smyd5 plays pivotal roles in both primitive and definitive hematopoiesis during zebrafish embryogenesis.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27377701","citation_count":29,"is_preprint":false},{"pmid":"35643234","id":"PMC_35643234","title":"Epithelial SMYD5 Exaggerates IBD by Down-regulating Mitochondrial Functions via Post-Translational Control of PGC-1α Stability.","date":"2022","source":"Cellular and molecular gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/35643234","citation_count":17,"is_preprint":false},{"pmid":"36897778","id":"PMC_36897778","title":"The lysine methyltransferase SMYD5 amplifies HIV-1 transcription and is post-transcriptionally upregulated by Tat and USP11.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/36897778","citation_count":15,"is_preprint":false},{"pmid":"39103523","id":"PMC_39103523","title":"SMYD5 is a ribosomal methyltransferase that catalyzes RPL40 lysine methylation to enhance translation output and promote hepatocellular carcinoma.","date":"2024","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/39103523","citation_count":13,"is_preprint":false},{"pmid":"35740908","id":"PMC_35740908","title":"Unique SMYD5 Structure Revealed by AlphaFold Correlates with Its Functional Divergence.","date":"2022","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/35740908","citation_count":11,"is_preprint":false},{"pmid":"35218722","id":"PMC_35218722","title":"SMYD5 acts as a potential biomarker for hepatocellular carcinoma.","date":"2022","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/35218722","citation_count":9,"is_preprint":false},{"pmid":"11861905","id":"PMC_11861905","title":"Glucose-inducible expression of rrg1+ in Schizosaccharomyces pombe: post-transcriptional regulation of mRNA stability mediated by the downstream region of the poly(A) site.","date":"2002","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/11861905","citation_count":6,"is_preprint":false},{"pmid":"38723947","id":"PMC_38723947","title":"Negative regulation of SH2B3 by SMYD5 controls epithelial-mesenchymal transition in lung cancer.","date":"2024","source":"Molecules and cells","url":"https://pubmed.ncbi.nlm.nih.gov/38723947","citation_count":5,"is_preprint":false},{"pmid":"33676231","id":"PMC_33676231","title":"Sperm chromatin-condensing protamine enhances SMYD5 thermal stability.","date":"2021","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/33676231","citation_count":5,"is_preprint":false},{"pmid":"39083378","id":"PMC_39083378","title":"SMYD5 is a regulator of the mild hypothermia response.","date":"2024","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/39083378","citation_count":3,"is_preprint":false},{"pmid":"40165083","id":"PMC_40165083","title":"Novel regulation mechanism of histone methyltransferase SMYD5 in rheumatoid arthritis.","date":"2025","source":"Cellular & molecular biology letters","url":"https://pubmed.ncbi.nlm.nih.gov/40165083","citation_count":1,"is_preprint":false},{"pmid":"37925635","id":"PMC_37925635","title":"A flow cytometry-based assay to investigate HIV-1 expression in SMYD5 shRNA containing primary CD4+ T cells.","date":"2023","source":"STAR protocols","url":"https://pubmed.ncbi.nlm.nih.gov/37925635","citation_count":1,"is_preprint":false},{"pmid":"40184250","id":"PMC_40184250","title":"SMYD5 is a ribosomal methyltransferase that trimethylates RPL40 lysine 22 through recognition of a KXY motif.","date":"2025","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/40184250","citation_count":0,"is_preprint":false},{"pmid":"12442907","id":"PMC_12442907","title":"A glucose-inducible gene in Schizosaccharomyces pombe, rrg1+, is involved in negative regulation of G2/M progression.","date":"2002","source":"Molecules and cells","url":"https://pubmed.ncbi.nlm.nih.gov/12442907","citation_count":0,"is_preprint":false},{"pmid":"40872497","id":"PMC_40872497","title":"SMYD5-BRD4 Interaction Drives Hepatocellular Carcinoma Progression: A Combined in Silico and Experimental Analysis.","date":"2025","source":"Pharmaceuticals (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/40872497","citation_count":0,"is_preprint":false},{"pmid":"37333301","id":"PMC_37333301","title":"SMYD5 is a regulator of the mild hypothermia response.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/37333301","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.10.10.616381","title":"SMYD5 is a ribosomal methyltransferase which trimethylates RPL40 lysine 22 through recognition of a KXY motif","date":"2024-10-11","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.10.616381","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":12376,"output_tokens":4321,"usd":0.050972,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":12230,"output_tokens":3226,"usd":0.0709,"stage2_stop_reason":"end_turn"},"total_usd":0.121872,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2022,\n      \"finding\": \"SMYD5 is a histone methyltransferase that catalyzes H3K36me3 at promoter regions (distinct from SETD2-mediated H3K36me3 at gene bodies). SMYD5 is recruited to chromatin by RNA polymerase II, and its enzymatic activity depends on its C-terminal glutamic acid-rich domain; overexpression of full-length but not C-terminal domain-truncated Smyd5 restores H3K36me3 at promoters in knockout cells.\",\n      \"method\": \"ChIP-seq, Smyd5 knockout rescue with full-length vs. truncated constructs, in vitro methyltransferase assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro enzymatic assay, domain truncation mutagenesis, and KO rescue with orthogonal ChIP-seq validation in a single rigorous study\",\n      \"pmids\": [\"35680905\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SMYD5 trimethylates the core ribosomal protein RPL40 (ubiquitin fusion protein partner) at lysine 22 (rpL40K22me3). This modification regulates mRNA translation output; loss of SMYD5 leads to reduced translation output and increased ribosome collisions indicative of disturbed elongation. Identified by a biochemical-proteomics strategy as the principal physiological substrate of SMYD5.\",\n      \"method\": \"Biochemical-proteomics (mass spectrometry), in vitro methyltransferase assay, ribosome profiling/polysome analysis, SMYD5 ablation in cell lines and mouse models\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro assay, MS-based substrate identification, replicated independently in multiple labs (PMID:39048817, PMID:39103523, PMID:40184250)\",\n      \"pmids\": [\"39048817\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SMYD5 has robust in vitro methyltransferase activity toward RPL40 K22 and primarily catalyzes RPL40 K22me3 in cells. Loss of SMYD5 and RPL40 K22me3 reduces translation output and causes increased ribosome collisions. SMYD5 and RPL40 K22me3 are upregulated in hepatocellular carcinoma.\",\n      \"method\": \"In vitro methyltransferase assay with recombinant SMYD5, SMYD5 knockout cell lines, ribosome fractionation/polysome profiling, genetically engineered mouse models and PDX models\",\n      \"journal\": \"Cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with recombinant protein, KO cells, polysome profiling, and in vivo mouse models; replicates findings from concurrent independent studies\",\n      \"pmids\": [\"39103523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SMYD5 trimethylates RPL40/eL40 at lysine 22 through recognition of a KXY motif (tyrosine at the +2 position is required). Active site mutations abolish this activity. SMYD5 does not methylate histones in vitro, and its requirement for the KXY motif explains this lack of activity toward canonical histone substrates. SMYD5 KO in K562 cells causes complete loss of RPL40 K22 methylation and decreased polysome levels.\",\n      \"method\": \"In vitro methyltransferase assay with recombinant SMYD5 and synthetic peptides, active-site mutagenesis, SMYD5 KO in K562 cells, mass spectrometry, systematic recognition motif analysis\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with mutagenesis, systematic motif analysis, KO validation, and negative result for histone substrates; all orthogonal methods in one study\",\n      \"pmids\": [\"40184250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SMYD5 does not methylate histones in vitro (negative finding). Systematic analysis of its recognition motif shows SMYD5 requires a KXY motif, and the absence of a tyrosine at +2 in canonical histone substrates explains its lack of histone methyltransferase activity.\",\n      \"method\": \"In vitro methyltransferase assay with recombinant SMYD5 toward histone substrates, systematic peptide motif analysis\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — rigorous in vitro assay with systematic motif mapping; explicitly tested and rejected histone substrates\",\n      \"pmids\": [\"40184250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"SMYD5 mediates H4K20me3 at heterochromatin regions in embryonic stem cells. Depletion of SMYD5 leads to global decreases in H4K20me3 levels, redistribution of heterochromatin constituents (H3K9me3/2, G9a, HP1α), and de-repression of endogenous retroelements (LTR, LINE elements). Loss of SMYD5-dependent heterochromatin silencing near genic regions upregulates lineage-specific genes, compromising ES cell self-renewal.\",\n      \"method\": \"ChIP-seq, SMYD5 knockdown in mouse ES cells, Western blot for histone marks, repeat element expression analysis\",\n      \"journal\": \"Epigenetics & chromatin\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KD with defined epigenomic phenotype, ChIP-seq, multiple histone mark readouts; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"28250819\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"SMYD5 depletion during ES cell differentiation causes genome-wide decreases in H4K20me3 and H3K9me3, derepression of LTR and LINE repetitive elements, chromosomal aberrations, and formation of transformed cells with a cancer-like expression signature. Depletion of SMYD5 in human colon and lung cancer cells increases tumor growth.\",\n      \"method\": \"SMYD5 depletion in mouse ES cells during differentiation, ChIP-seq, cytogenetics/karyotyping, xenograft tumor assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KD with defined cellular phenotypes (chromosomal aberrations, epigenomic changes), multiple orthogonal methods, single lab\",\n      \"pmids\": [\"28951459\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SMYD5 interacts with PGC-1α (co-immunoprecipitation) and mediates lysine methylation of PGC-1α, subsequently facilitating its ubiquitination and degradation. This post-translational mechanism attenuates mitochondrial biogenesis, respiration, and function in intestinal epithelial cells. Smyd5 conditional knockout in IECs protects mice from DSS-induced colitis.\",\n      \"method\": \"Co-immunoprecipitation, in vitro methylation assay with mass spectrometry identification of methylated lysines, cycloheximide chase assay, Smyd5 conditional KO mice with colitis model, Seahorse respirometry\",\n      \"journal\": \"Cellular and molecular gastroenterology and hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP, in vitro methylation with MS, degradation assay, and in vivo KO model; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"35643234\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SMYD5 associates in vivo with the HIV-1 promoter, binds the HIV-1 TAR element RNA and Tat protein, and methylates Tat in vitro. SMYD5 activates the HIV-1 promoter with or without Tat; knockdown of SMYD5 decreases HIV-1 transcription in cell lines and primary CD4+ T cells. Tat expression increases SMYD5 protein levels in a manner dependent on the Tat cofactor USP11.\",\n      \"method\": \"ChIP assay (in vivo promoter association), RNA binding assay (TAR element), in vitro methylation assay (Tat substrate), SMYD5 knockdown in cell lines and primary T cells, HIV-1 transcription reporter assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro methylation of Tat, ChIP, RNA binding, and functional KD in primary cells; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"36897778\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SMYD5 represses the key mild hypothermia response (MHR) gene SP1 at euthermia; this repression correlates with temperature-dependent levels of H3K36me3 at the SP1 locus and globally, identified through a forward CRISPR-Cas9 mutagenesis screen.\",\n      \"method\": \"Forward CRISPR-Cas9 mutagenesis screen, ChIP analysis for H3K36me3, transcriptional reporter/gene expression assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR screen plus correlative H3K36me3 ChIP; mechanistic link to SMYD5 enzymatic activity inferred but not directly demonstrated via mutagenesis\",\n      \"pmids\": [\"39083378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Loss of Smyd5 in zebrafish (morpholino knockdown and CRISPR/Cas9 knockout) leads to increased expression of primitive and definitive hematopoietic markers (pu.1, mpx, l-plastin, cmyb), establishing a role for Smyd5 in restraining myeloid hematopoiesis during embryogenesis.\",\n      \"method\": \"Morpholino knockdown, CRISPR/Cas9 knockout in zebrafish embryos, in situ hybridization and RT-PCR for hematopoietic markers\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two independent loss-of-function approaches (MO + CRISPR) with consistent phenotypic readout in zebrafish; no direct biochemical mechanism defined\",\n      \"pmids\": [\"27377701\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"AlphaFold structural modeling of SMYD5 reveals an incomplete target lysine access channel lacking the evolutionarily conserved tri-aromatic arrangement, which correlates with low H3/H4 histone catalytic activity. SMYD5 contains a C-terminal poly-glutamic acid tract and a 30-residue MYND domain insertion that regulate structural stability, and a predicted N-terminal mitochondrial targeting signal containing a non-classical nuclear localization signal.\",\n      \"method\": \"AlphaFold structural prediction validated by comparison to known SMYD crystal structures using inter-residue distance maps; thermal stability assays\",\n      \"journal\": \"Biomolecules\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Weak — primarily computational structural prediction with some biochemical correlation; no direct experimental structure determination or mutagenesis of active site residues\",\n      \"pmids\": [\"35740908\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Protamine (a histone substitute in chromatin condensation during spermatogenesis) enhances SMYD5 thermal stability and physically interacts with SMYD5. The interaction is independent of the poly-E tract and MYND domain insertion. The C-terminal poly-glutamic acid tract and MYND domain M-insertion also regulate SMYD5 structural stability. Protamine has opposite (destabilizing) effects on the closely related SMYD2.\",\n      \"method\": \"Thermal stability assay (DSF), machine learning-assisted screening (Silver Bullets Bio library), co-precipitation/binding assays for protamine-SMYD5 interaction\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — thermal stability and binding assays in a single study; functional consequence of protamine-SMYD5 interaction not established\",\n      \"pmids\": [\"33676231\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SMYD5 knockdown in lung cancer cell lines reduces H4K20 trimethylation at the SH2B3 locus, leading to increased SH2B3 expression and inhibition of cell migration and invasion via changes in epithelial-mesenchymal transition markers and MMP9 expression.\",\n      \"method\": \"SMYD5 knockdown in NCI-H1299 and H1703 cell lines, ChIP for H4K20me3, migration/invasion assays, EMT marker analysis\",\n      \"journal\": \"Molecules and cells\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single KD approach, correlative ChIP without direct methyltransferase activity demonstration\",\n      \"pmids\": [\"38723947\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SMYD5 mediates methylation of FoxO1 in fibroblast-like synoviocytes, which accelerates FoxO1 degradation through ubiquitination, promoting FLS proliferation. Additionally, SMYD5 promotes upregulation of hexokinase-2 (HK2), increasing lactate release and activating NF-κB signaling to intensify inflammation in FLS.\",\n      \"method\": \"Loss-of-function and gain-of-function experiments in FLS, co-immunoprecipitation (inferred from context), AAV-mediated KD in CIA mouse model, downstream pathway analysis\",\n      \"journal\": \"Cellular & molecular biology letters\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, mechanistic details (direct methylation of FoxO1) described but no explicit in vitro methylation assay reported in abstract\",\n      \"pmids\": [\"40165083\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SMYD5 physically interacts with BRD4 in hepatocellular carcinoma cells; this interaction is identified as a potential therapeutic axis. Knockdown of SMYD5 inhibits cell proliferation and increases apoptosis in LIHC cell lines.\",\n      \"method\": \"Co-immunoprecipitation (interaction), functional knockdown assays, bioinformatics/in silico docking\",\n      \"journal\": \"Pharmaceuticals (Basel, Switzerland)\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, interaction reported but mechanistic detail of BRD4-SMYD5 functional axis not fully characterized in the abstract\",\n      \"pmids\": [\"40872497\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SMYD5 is a SET and MYND domain-containing lysine methyltransferase whose principal physiological substrate is the ribosomal protein RPL40, which it trimethylates at lysine 22 via recognition of a KXY motif to promote translation elongation; SMYD5 also catalyzes H3K36me3 at gene promoters (recruited by RNA Pol II) to regulate gene expression, and has been shown to methylate non-histone proteins including PGC-1α (promoting its ubiquitin-dependent degradation to impair mitochondrial function) and the HIV-1 Tat protein (activating viral transcription), while its role in H4K20me3-marked heterochromatin maintenance in stem cells—previously its primary described function—may reflect indirect effects given that in vitro evidence argues against direct histone methylation activity.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SMYD5 is a SET- and MYND-domain lysine methyltransferase whose principal physiological substrate is the core ribosomal protein RPL40/eL40, which it trimethylates at lysine 22 to support mRNA translation [#1, #2]. Substrate selection is governed by recognition of a KXY motif requiring a tyrosine at the +2 position, and active-site mutations abolish catalysis [#3]. Loss of SMYD5 eliminates RPL40 K22me3, reduces translation output, increases ribosome collisions indicative of disturbed elongation, and lowers polysome levels [#1, #2, #3]. SMYD5 and RPL40 K22me3 are upregulated in hepatocellular carcinoma [#2]. Beyond this ribosomal role, SMYD5 catalyzes H3K36me3 at promoter regions in a manner dependent on its C-terminal glutamic acid-rich domain and is recruited to chromatin by RNA polymerase II, distinct from SETD2-mediated H3K36me3 at gene bodies [#0]. SMYD5 also methylates non-histone proteins: it methylates PGC-1\\u03b1 to promote its ubiquitin-dependent degradation, attenuating mitochondrial biogenesis and respiration [#7], and methylates the HIV-1 Tat protein while associating with the HIV-1 promoter and TAR RNA to activate viral transcription [#8]. In vitro reconstitution with recombinant SMYD5 shows no direct methylation of canonical histones, since these substrates lack the required +2 tyrosine, indicating that earlier-described H4K20me3-related heterochromatin functions in stem and cancer cells [#5, #6] reflect activities not explained by direct histone methylation [#3, #4]. No experimentally determined structure of SMYD5 is available in this corpus.\",\n  \"teleology\": [\n    {\n      \"year\": 2017,\n      \"claim\": \"Established the first proposed chromatin function of SMYD5, linking it to H4K20me3-marked heterochromatin maintenance, retroelement silencing, and stem cell self-renewal versus tumorigenesis.\",\n      \"evidence\": \"SMYD5 knockdown/depletion in mouse ES cells with ChIP-seq, histone mark Westerns, repeat element expression, cytogenetics, and xenograft assays\",\n      \"pmids\": [\"28250819\", \"28951459\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No direct in vitro demonstration that SMYD5 methylates H4K20\", \"Effects could be indirect rather than via direct catalysis\", \"Recruitment mechanism to heterochromatin undefined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrated an in vivo developmental role for Smyd5 in restraining myeloid hematopoiesis, the first organismal phenotype for the gene.\",\n      \"evidence\": \"Morpholino knockdown and CRISPR/Cas9 knockout in zebrafish with in situ hybridization and RT-PCR for hematopoietic markers\",\n      \"pmids\": [\"27377701\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No biochemical substrate or molecular mechanism defined\", \"Does not connect phenotype to a specific methylation event\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Resolved SMYD5's chromatin enzymatic activity by assigning it promoter-localized H3K36me3 distinct from SETD2 gene-body marks and showing the C-terminal domain is required for activity.\",\n      \"evidence\": \"ChIP-seq, knockout rescue with full-length versus truncated constructs, and in vitro methyltransferase assay\",\n      \"pmids\": [\"35680905\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Reconciliation with later negative histone methylation results unresolved\", \"Mechanism of RNA Pol II-mediated recruitment not detailed\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Extended SMYD5 to non-histone substrate methylation by showing it methylates PGC-1\\u03b1 to drive its degradation, coupling SMYD5 to mitochondrial function and intestinal inflammation.\",\n      \"evidence\": \"Co-IP, in vitro methylation with MS, cycloheximide chase, conditional KO mice, and Seahorse respirometry\",\n      \"pmids\": [\"35643234\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific methylated lysines and their direct role in ubiquitination not fully mapped\", \"Single lab\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified a host-pathogen role in which SMYD5 binds the HIV-1 promoter, TAR RNA, and Tat, and methylates Tat to activate viral transcription.\",\n      \"evidence\": \"ChIP, RNA binding assay, in vitro methylation of Tat, and SMYD5 knockdown in cell lines and primary CD4+ T cells\",\n      \"pmids\": [\"36897778\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Site and functional consequence of Tat methylation not fully resolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Redefined the principal physiological substrate of SMYD5 as ribosomal protein RPL40 K22, connecting the enzyme directly to translation elongation rather than chromatin.\",\n      \"evidence\": \"Biochemical-proteomics/MS substrate identification, in vitro methyltransferase assays, ribosome/polysome profiling, and SMYD5 ablation in cells and mouse models, replicated across independent labs\",\n      \"pmids\": [\"39048817\", \"39103523\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How RPL40 K22me3 mechanistically prevents ribosome collisions unresolved\", \"Relationship between translation role and prior chromatin phenotypes unclear\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Defined the substrate-recognition logic (KXY motif, +2 tyrosine) and experimentally rejected direct histone methylation, reframing earlier histone-mark phenotypes as likely indirect.\",\n      \"evidence\": \"In vitro methyltransferase assays with recombinant SMYD5 and synthetic peptides, active-site and motif mutagenesis, MS, and KO validation in K562 cells including negative histone results\",\n      \"pmids\": [\"40184250\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanistic basis of in-cell H3K36me3 ChIP signals not reconciled with in vitro negativity\", \"Full census of KXY-bearing cellular substrates incomplete\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Expanded the disease-context substrate and interaction repertoire (FoxO1 methylation/degradation and metabolic-inflammatory signaling in synoviocytes; BRD4 interaction in hepatocellular carcinoma).\",\n      \"evidence\": \"Loss/gain-of-function in fibroblast-like synoviocytes with AAV KD in a CIA mouse model, and co-IP plus functional knockdown in LIHC cell lines\",\n      \"pmids\": [\"40165083\", \"40872497\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No explicit in vitro methylation assay reported for FoxO1\", \"BRD4-SMYD5 functional axis not mechanistically characterized\", \"Single-lab, correlative associations\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how SMYD5's ribosomal RPL40 methylation activity mechanistically relates to the chromatin-associated H3K36me3 and heterochromatin phenotypes attributed to it, and whether the latter depend on its catalytic activity.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No experimental structure of SMYD5\", \"No unifying model linking translation and chromatin functions\", \"Direct catalytic basis of in-cell histone marks undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 1, 2, 3, 7, 8]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [1, 2, 3, 7, 8]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 5, 8]},\n      {\"term_id\": \"GO:0005840\", \"supporting_discovery_ids\": [1, 2, 3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [1, 2, 3]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [0, 5, 6]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [7]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"RPL40\", \"PGC-1\\u03b1\", \"Tat\", \"BRD4\", \"FoxO1\", \"protamine\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}